u/osman_ferrari

I would not read one pharmacy’s cash price as the going rate. The spread is real.

the lowest effective dose is a real target and nobody talks about it

I would push back gently. Going up because the scale paused is the single most common mistake described on this board.

Certain conditions affect A1c independently of glycaemia. If a result looks inconsistent with the sensor data, that is a question for whoever manages your care rather than for this board.

Internal appeals are decided by the plan.

vikram_mbeki is right that this is documentation rather than persuasion. It took me a year to accept that.

do not chase somebody else’s titration schedule, they are not you

prior authorisation criteria change every plan year

A1c is a three-month average and it lags everything

My ApoB moved and it turned out to have nothing to do with glucose at all.

Correction: that trial is the diabetes programme and the figure you quoted is its glycaemic endpoint, not a weight result.

stretching the interval is not the same as reducing the dose

Maintenance is the phase with the least published guidance and the most individual variation, which is precisely why board consensus here is worth less than usual.

The diabetes and obesity programmes are separate, with different populations and different primary endpoints. Reading a result across from one to the other is not a comparison.

Interval stretching changes the exposure profile: with a week-long half-life, moving to ten or twelve days lowers trough concentration more than it lowers average exposure. That is why appetite return is often the first thing noticed.

Employer plan or individual plan?

Standing reminder: research-use-only material is not approved for human use, and no outcome claims without evidence.

Agreed — and the naming problem is worse than most people here realise.

That result is an area percent from an unspecified method, which is not the same as the identity confirmation being discussed.

handling and storage vary enormously across this catalogue

Correction: that is a formulary exclusion, not a prior authorisation denial. Different form, different route, different deadline.

Small fix — insulin secretion in this class is glucose-dependent, which is precisely why the risk you describe comes from the other agent.

A1c reflects average glycaemia over roughly the preceding three months, weighted towards the most recent weeks. It cannot show variability and it lags any change you make.

Agreed. The denial letter tells you which criterion failed, and answering that specific criterion is the entire job.

That reads like a titration plan and this board cannot give you one. Somebody who actually knows your history has to.

Formulary criteria are revised, and plan renewal is a natural point at which a previously refused request may succeed without anything about the applicant changing.

protein first, then everything else gets easier

I would not compare your numbers to that population. Different baseline, different regimen, different trial.

Correcting myself upthread: the deadline was 10 days, not the figure I gave.

Careful — the deadline runs from the date on the letter. Waiting for a call back can cost you the appeal entirely.

Body weight varies by a couple of kilos over days in stable people through fluid, glycogen and gut content. A range is not a trend.

nausea that arrives on day two and fades by day four is the standard shape

a peer-to-peer call is often faster than a written appeal

Documented eighteen months of what had been tried in a one-page table. That table was the appeal.

Yes. Written, always, even when they tell you a phone call is sufficient.

Agreed. The denial letter tells you which criterion failed, and answering that specific criterion is the entire job.